Introduction
© 2015 Wichtig Publishing and social life and in their sports activities, attributable primarily to the presence of related pain (13, 14) .
Effective long-term management of endometriosis is a significant clinical objective in view of the debilitating nature of this chronic condition. Among current management approaches, surgery and hormonal drugs are considered as primary treatment or to reduce the recurrences.
The current cure for endometriosis is surgical and/or medical. Surgery is a common treatment choice, but recurrence rates are high: approximately 40%-50% after 5 years (15, 16) . Approved medical treatments for relief of the symptoms of endometriosis include gonadotropin-releasing hormone (GnRH) analogs and danazol. Both of these classes of treatment may be used as primary treatment and after surgery. However, both drugs are associated with suboptimal safety and tolerability that limit their long-term use (17) . A number of progestins offer long-term efficacy but, depending on their pharmacologic profile, can cause weight gain or androgenic effects at the high doses required for efficacy (18) .
Dienogest offers unique pharmacological targets relevant to the treatment of endometriosis, including potent progestogenic effects that lead to effective endometrial lesion reduction, combined with moderate suppression of estrogen levels (19) and reduction of inflammatory mechanisms (20) and of angiogenesis (21) .
Dienogest treatment for periods of 12-24 weeks has been reported to be superior in efficacy in comparison with placebo (22) and equivalent to leuprolide acetate and buserelin acetate (23, 24) . Long-term studies (22, 25, 26) have also revealed a decrease of endometriosis-associated pain, with limited adverse events (mostly mild or moderate in intensity), associated with low discontinuation rates.
The present prospective study aimed to evaluate the effect of dienogest on quality of life during treatment for endometriosis.
Materials and methods
The present prospective, observational, multicenter, cohort study aimed to evaluate quality of life in endometriotic women treated with dienogest.
Women were eligible for the study if aged from 18 years, with diagnosis of endometriosis associated with visual analogue scale (VAS) pelvic pain score from 0 to 10 cm at start of treatment, waiting for surgery or in patients with previous surgery for endometriosis and recurrent pelvic pain (Tab. I). Exclusion criteria were the simultaneous presence of uterine benign disorders such as uterine fibroids and endometrial polyps, and malignant uterine and ovarian pathologies. Recruitment was completed when the foreseen sample size in all participating centers (competitive recruitment) was reached. A group of 142 patients was enrolled; with mean age of 34.9 years (SD = 6.5).
Dienogest (2 mg) was administered once daily, for up to 90 days. At study entry, general characteristics and clinical information regarding diagnosis of endometriosis were collected. A VAS value was collected. Further, the patient was asked to fill out the Short Form 12 (SF-12; see below) quality-of-life questionnaire and to come back after 30 days (V1).
Quality of life was measured using the SF-12 questionnaire. This questionnaire is a well-known 12-item generic quality-of-life measure that assesses physical and mental functioning over the previous 4 weeks. Scores range from 0 to 100 for each dimension, with 100 indicating optimal quality of life (27, 28) . Baseline to V2 (90 days after study entry) differences in the VAS and SF-12 questionnaire score were computed.
At V1 (30 days), the patient was interviewed on their regular intake of dienogest and any clinical symptoms or adverse events (AEs), including bleeding. In case of discontinuation of dienogest treatment, reason for discontinuation was collected. Women were also requested to assess endometriosis-related pelvic pain using the VAS. The patient was also asked to continue the treatment and to come back again after 60 days (i.e., total of 90 days after study entry, V2). At V2, the patient was interviewed again on the regular intake of dienogest, clinical symptoms and AEs. She was also asked to assess VAS scale pelvic pain intensity and fill out the SF-12 questionnaire.
AEs were documented at all study visits and coded according to the appropriate Medical Dictionary for Regulatory Activities primary system organ class. The use of any concomitant medications for pain was also recorded in all visits. The institutional review committees of the participating centers approved the study. All women signed an informed consent form.
Sample size
Literature data indicate that in patients with VAS average equal to 4, the expected average reduction of the value of VAS after treatment for 3 month with dienogest is 2.0, with standard deviation (SD) 2.0 (15) . We foresaw including 100 patients. With such a sample size, we would be able to evaluate a mean change from baseline VAS of 0.8 or greater (minimum reduction deemed significant from a clinical point of view), with SD = 2.0, at the usual levels of alpha (0.05) and beta (0.20). To make up for a possible dropout rate of about 15%, the sample size was increased to 118.
Statistical analysis
Descriptive statistics -mean (SD), median (interquartile range [IQR]) and frequency (%) -were used to describe the study population. Baseline to V2 differences in the VAS and SF-12 questionnaire scores were computed, and the statistical significance of changes from baseline was evaluated by paired t-test. Values are means ± standard deviation, or number (%), as indicated.
Results
Pain Table II shows the distribution of study subjects at entry and follow-up visit according to VAS values. The mean ± SD VAS score at baseline was 8.0 ± 1.7 in the total series. The VAS score progressively and significantly decreased (p<0.01) to 5.2 ± 2.5 at the end of the study (V2) in the total population (Tab. II).
Quality of life (SF-12 questionnaire)
The mean scores for physical and mental components of the SF-12 are shown in Table III . The mental index score values increased in the total series from 39.0 ± 9.8 to 46.0 ± 9.1 (p<0.001). Likewise, the physical index increased from 39.6 ± 9.6 to 47.7 ± 8.5 (p<0.001).
Adverse events
The most frequent AE was headache (30.8%), followed by bleeding (29.4%; for a median duration of 7 days, IQR 4-20), depression (26.6%), breast tenderness (23.8%) and acne (2.0%). Mostly, AEs grade was described as moderate (47.7%), and the dropout rate of patients was 4%.
Discussion
The present study showed that dienogest is effective in increasing the quality of life in women with endometriosis.
The impact of endometriosis on reducing the quality of life is substantial and wide ranging (6) (7) (8) (9) (10) (11) (12) (13) (14) . Quality-of-life assessments in the present study showed improvements in both physical and mental indices within 12 weeks, also confirming the decrease of endometriosis-associated pain (22) (23) (24) (25) .
Randomized clinical trials and clinical series have consistently shown that dienogest is effective in the treatment of pain-related endometriosis (22) (23) (24) (25) . Our original finding is the analysis of the effect of dienogest on the mental and physical SF index scores values, which increased during the 3-month study period by about 15%. The painful chronic symptoms of endometriosis are known to be a causal factor of poor quality of life in endometriotic women, and various instruments (e.g., SF-36®, SF-12®, EQ-5D, Duke Health Profile) have been used to measure effects on quality of life and health-related problems in patients with endometriosis (29) . Endometriosis significantly affects women and societies worldwide (30) . Dyspareunia and chronic pain are 2 factors affecting both physical and mental components of quality of life. Awareness of these symptoms in primary care may lead in the future to earlier diagnosis, to less suffering and to improved work productivity (30) .
Pain and reduced quality of life may also induce high levels of perceived stress in women with the various forms of endometriosis and are correlated with the most severe form (deep infiltrating endometriosis) (31) . Stress is reduced by surgical or medical treatment to relieve pain; the most effective approach to reducing stress is progestin long-term therapy (32) .
An empirical dienogest treatment option for women without laparoscopic confirmation represents a suitable adjuvant therapy before undergoing surgery (33) . An effective long-term management of endometriosis after surgery is a significant clinical objective in view of the debilitating nature of this chronic condition. Among current management approaches, recurrence is common after surgery, and the search for a medical treatment is an important goal. A previous study has shown that oral contraception pills are useful in this direction in woman operated on for endometriosis (34) . The present study suggests the use of dienogest for this purpose. The safety analysis of the study indicated an acceptable profile for dienogest in routine clinical practice. In fact, only 6 cases (4%) of interruption of treatment were permanent, which is similar or lower to the rates reported in previous randomized clinical trials. In particular, irregular bleeding was reported to be present for a mean 7 days over the 3-month study period.
Potential limitations of this study to be considered are the observational form and the lack of control group. This design Values are means (standard deviation). V2 = at 90 days from start of treatment.
was chosen to evaluate the use of dienogest in routine clinical practice, and perspective cases were consecutively identified in the participating centers.
In conclusion, this prospective study showed that dienogest improves quality of life in women with endometriosis, supporting the possible use of this drug as primary or secondary treatment for endometriosis.
